Graybug Vision Inc.

5.06-0.8100-13.80%Vol 4.25M1Y Perf -69.88%
Jun 14th, 2021 16:00 DELAYED
BID5.07 ASK5.08
Open5.48 Previous Close5.87
Pre-Market- After-Market-
 - -  - -%
Target Price
4.75 
Analyst Rating
— — 0.00
Potential %
-6.13 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap106.54M 
Earnings Rating
Price Range Ratio 52W %
4.73 
Earnings Date
3rd Jun 2021

Today's Price Range

4.915.69

52W Range

3.4337.88

Summary:

Neutral

Technical Indicators: Buy
Moving Averages: Neutral
Performance
1 Week
4.98%
1 Month
39.78%
3 Months
-40.40%
6 Months
-80.45%
1 Year
-69.88%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
GRAY5.06-0.8100-13.80
AAPL130.483.13002.46
GOOG2 527.0413.11000.52
MSFT259.892.00000.78
XOM62.07-0.1000-0.16
WFC45.15-0.5300-1.16
JNJ165.370.41000.25
FB336.775.51001.66
GE13.47-0.2200-1.61
JPM157.57-2.7200-1.70
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.45-0.54-20.00
Q03 2020-0.62-3.27-427.42
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.45
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume4.25M
Shares Outstanding21.06M
Trades Count19.62K
Dollar Volume894.12K
Avg. Volume1.01M
Avg. Weekly Volume10.83M
Avg. Monthly Volume3.18M
Avg. Quarterly Volume1.56M

Graybug Vision Inc. (NASDAQ: GRAY) stock closed at 5.06 per share at the end of the most recent trading day (a -13.8% change compared to the prior day closing price) with a volume of 4.29M shares and market capitalization of 106.54M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 31 people. Graybug Vision Inc. CEO is Frederic Guerard.

The one-year performance of Graybug Vision Inc. stock is -69.88%, while year-to-date (YTD) performance is -82.56%. GRAY stock has a five-year performance of %. Its 52-week range is between 3.43 and 37.88, which gives GRAY stock a 52-week price range ratio of 4.73%

Graybug Vision Inc. currently has a PE ratio of 1.10, a price-to-book (PB) ratio of 1.46, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -40.81%, a ROC of -43.93% and a ROE of -43.84%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Graybug Vision Inc., there were 0 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.45 for the next earnings report. Graybug Vision Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Graybug Vision Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Graybug Vision Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Graybug Vision Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Graybug Vision Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 31.19, ATR14 : 0.63, CCI20 : 128.19, Chaikin Money Flow : 0.06, MACD : 0.20, Money Flow Index : 88.51, ROC : 36.39, RSI : 57.19, STOCH (14,3) : 44.96, STOCH RSI : 0.32, UO : 46.90, Williams %R : -55.04), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Graybug Vision Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Graybug Vision Inc.

Graybug Vision Inc is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. The company's products under pipeline are GB-102, for the treatment of wet age-related macular degeneration, or wet AMD, and diabetic macular edema, or DME; GB-103; and GB-401.

CEO: Frederic Guerard

Telephone: +1 650 487-2800

Address: 275 Shoreline Drive, Redwood City 94065, CA, US

Number of employees: 31

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

67%33%

News

Stocktwits